Having trouble accessing articles? Reset your cache.

Simponi golimumab regulatory update

The U.K.'s NICE issued a preliminary appraisal recommending against Simponi golimumab from Johnson & Johnson and Merck to treat active and progressive

Read the full 225 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE